-
Most Recent
Search Results
240 results for abv
AI Infrastructure Stocks Are Leaving the ‘Old Economy’ Behind
AI infrastructure stocks are surging while traditional firms struggle. Earnings reveal a growing economic divide investors can’t ignore.
Every Stock Has a Tell – Here’s How to Read Them
In today’s issue, Keith Kaplan explains how former New England Patriots coach Bill Belichick led his team to victories by creating behavior profiles for his…
Gold or Silver – Which Do You Buy Right Now?
The gold-to-silver ratio resets to equilibrium… Luke’s case for a silver melt-up… Eric’s case for gold… the fiscal disorder fueling the longer-term bet… so, which…
What the PCE Is Really Telling Investors Today
The ceasefire is fragile – but appears to be holding… this morning’s PCE confirms inflation is creeping higher… and what investors should be thinking about…
The AI Grid Is Leaving Earth
Orbital data centers could solve AI’s biggest constraints – power, cooling, and scale – creating a massive new investment opportunity.
You Can Now See What Wall Street Can’t
In today’s issue, Keith Kaplan explains how his team is using AI to identify specific “signals” in the market — patterns that have historically led…
Three Stocks for the AI Infrastructure Boom
114% gains on POET from Jonathan Rose… where he’s looking now… the electricity grid that can’t keep up… how Brian Hunt is investing… Nvidia’s quantum…
The Biggest AI Story You Missed
Claude’s Mythos causes cybersecurity stocks to tank… the quantum threat to online security is coming fast… how Jonathan Rose is playing it… has the energy…
When “AI” Became the New “Dot Com”
The dot-com playbook is back… AI’s gains are going to fewer companies than you think… how to trade when narratives mislead… tomorrow’s AI Signals Trading…
ABM’s Dividend Increase Won’t Keep it Above $30
This morning I am recommending a bearish trade on ABM Industries, Inc. (NYSE:ABM), a provider of facility services like parking, janitorial services and building and…
Trade of the Day: AbbVie (ABBV)
In 2017, Humira raked in $18.9 billion in sales for AbbVie (ABBV) and, according to the company’s latest earnings announcement, that sales rate grew by…
3 Energy Stocks to Buy Now
In this week’s Navellier Market Buzz, I talk about three energy stocks that are positioned to win in this chaotic environment, along with my top…
The Rubik’s Cube Secret to Better Trades
In this piece, Keith Kaplan shows you some examples of signal-based trades that outperformed the S&P 500 by roughly 3-to-1… plus he’s giving you access…
Strong Buy for AbbVie (ABBV) This Week
AbbVie (ABBV) remains a Strong Buy this week based on the most current relative pricing of its shares and analysis.
Strong Buy for AbbVie (ABBV) This Week
The Strong Buy for AbbVie (ABBV) this week is based on the latest stock market rankings, and relative pricing of its shares.
Strong Buy for AbbVie (ABBV) This Week
At $114.93, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
Strong Buy for AbbVie (ABBV) This Week
At $118.94, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
Why the Latest Inflation Numbers Look Hideous – And May Get Worse…
In today’s Market 360, I want to walk you through what the CPI and PCE reports are really telling us, what they may be missing…
What Big Bank Earnings Aren’t Telling Investors Right Now
Let’s look at what three big bank earnings reports are really telling us. Then I’ll show you why that matters for what comes next –…
AbbVie (ABBV) a Buy on Healthy Earnings Momentum
AbbVie Inc (NYSE:ABBV) is ranked as a Buy using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no…
AbbVie (ABBV) a Buy on Strong Quant Score
Currently, AbbVie Inc (NYSE:ABBV) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. ABBV has maintained this…
AbbVie (ABBV) a Buy on Robust Quant Score
AbbVie Inc (NYSE:ABBV) is a $147.1 billion in market value member of the Biotechnology GICS industry group where the stock’s current Portfolio Grader score places…
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
6 – 10 of 240 results
